The Takeda Pharmaceutical Company’s headquarters in Chuo-ku, Osaka, Japan. Credit: J o / commons.wikimedia.org.

Takeda has reported a 12.8% increase in its reported revenue to $29.96bn (Y4,027bn) during the fiscal year 2022 (FY2022) compared to that reported in FY2021.

At a constant exchange rate (CER), the company’s core revenue grew by 3.5% compared to the previous year.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

In the FY2022 ending 31 March 2023, the company also reported a 6.4% rise in its operating profit to $3.65bn (Y490.5bn) compared to 2021.

Reported earnings per share (EPS) grew by 38.8% to $1.5bn (Y204bn) and net profit for FY2021 increased by 37.8% to $2.36bn (Y317bn).

The same fiscal year recorded a 13% decline to $7.27bn (Y977.2bn) in operating cash flow.

The company has provided commercial updates across its five key business areas: gastroenterology (GI), rare diseases, plasma-derived therapy (PDT) immunology, oncology and neuroscience.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Its GI business reported an 8.7% increase in revenue to $8.145bn (Y1,094.5bn) on a CER basis.

Entyvio, for ulcerative colitis (UC) and Crohn’s disease (CD), steered the growth in the revenue of this business.

Rare diseases reported revenue growth of 4.8% to $5.38bn (Y723.4bn) and PDT immunology reported growth of 15.3% to $5.048bn (Y678.4bn), both on a CER basis.

Oncology reported a 14.4% decline in reported revenue on a CER basis to $3.26bn (Y438.7bn).

In neuroscience, reported revenue rose by 12.1% to $4.75bn (Y637.7bn) on a CER basis.

Takeda chief financial officer Costa Saroukos stated: “I’m pleased to report that Takeda delivered or exceeded management guidance in FY2022 and booked a record core operating profit of almost Y1.2tn.

“Our topline and profit performance was driven by our growth and launch products, which grew 19% at a constant exchange rate.

“Strong financial discipline and free cash flow have enabled us to deleverage rapidly while investing in growth.”